Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Shares Outstanding (Weighted Average): 2016-2025

Historic Shares Outstanding (Weighted Average) for UroGen Pharma (URGN) over the last 9 years, with Sep 2025 value amounting to $46.3 million.

  • UroGen Pharma's Shares Outstanding (Weighted Average) rose 9.85% to $46.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.3 million, marking a year-over-year increase of 9.85%. This contributed to the annual value of $42.2 million for FY2024, which is 36.72% up from last year.
  • Per UroGen Pharma's latest filing, its Shares Outstanding (Weighted Average) stood at $46.3 million for Q3 2025, which was up 0.34% from $46.1 million recorded in Q2 2025.
  • UroGen Pharma's Shares Outstanding (Weighted Average)'s 5-year high stood at $46.3 million during Q3 2025, with a 5-year trough of $22.3 million in Q1 2021.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $36.5 million, with a median of $36.1 million in 2024.
  • Data for UroGen Pharma's Shares Outstanding (Weighted Average) shows a peak YoY soared of 54.05% (in 2024) over the last 5 years.
  • Over the past 5 years, UroGen Pharma's Shares Outstanding (Weighted Average) (Quarterly) stood at $22.4 million in 2021, then climbed by 2.99% to $23.1 million in 2022, then soared by 33.68% to $30.9 million in 2023, then soared by 36.72% to $42.2 million in 2024, then increased by 9.85% to $46.3 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $46.3 million for Q3 2025, versus $46.1 million for Q2 2025 and $46.1 million for Q1 2025.